Ensign Peak Advisors, Inc Prelude Therapeutics Inc Transaction History

Ensign Peak Advisors, Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	BUY	$11.89 - $31.74 $96,071 - $256,459	8,080 New	8,080 $101,000
Q2 2021 Aug 13, 2021	SELL	$28.63 - $44.3 $500,967 - $775,161	-17,498 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$39.27 - $91.68 $687,146 - $1.6 Million	17,498 New	17,498 $758,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $35.6M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.